Evaluation of Enoxaparin for Inpatient Venous Thromboembolism Prophylaxis in End-Stage Renal Disease Patients on Hemodialysis.

ABSTRACT: Background: Enoxaparin is not recommended for venous thromboembolism (VTE) prophylaxis in the end-stage renal disease (ESRD) on hemodialysis (HD) population due to concerns for drug accumulation and increased bleeding risk. Due to the paucity of literature with clinical outcomes to support this theoretical safety concern, the purpose of this study was to compare the risks of bleeding of enoxaparin and unfractionated heparin (UFH) in hospitalized, HD-dependent patients. Methods: This retrospective cohort study examined ESRD on HD patients who received either subcutaneous enoxaparin or UFH for VTE prophylaxis and were admitted for at least 48 hours. The primary outcome was major bleeding or clinically relevant non-major bleeding (CRNMB) as guided by definitions from the Interna

SUBMITTER: Sacks J 

PROVIDER: S-EPMC8559058 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature